Skip to main content
GENEDRIVE PLC logo

GENEDRIVE PLC — Investor Relations & Filings

Ticker · GDR ISIN · GB00B1VKB244 LEI · 213800ZYODIRZ87Y4K14 IL Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2020-05-07 Regulatory Filings
Country GB United Kingdom
Listing IL GDR

About GENEDRIVE PLC

https://genedriveplc.com/

Genedrive PLC is a molecular diagnostics company specializing in the development and commercialization of a rapid, point-of-care pharmacogenetic testing platform. The company's core technology, the Genedrive® System, is designed for the swift diagnosis of genetic variants to enable personalized medicine in critical care settings. Its key products include the Genedrive® MT-RNR1 ID Kit, used to prevent antibiotic-induced hearing loss in infants, and the Genedrive® CYP2C19 ID Kit, which helps optimize antiplatelet therapy for stroke patients. The platform empowers clinicians to make safer and more effective treatment decisions by providing crucial genetic information at the point of need, thereby improving patient outcomes.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1353 characters) and begins with an 'RNS Number' and the date, indicating it is a regulatory news service announcement from the London Stock Exchange. The content specifically discusses a 'Price Monitoring Extension' for a security, which is a procedural update related to trading mechanics, not a core financial report (like 10-K, ER, or IR). Since it is a general regulatory announcement that doesn't fit the specific categories like DIRS, DIV, or DLST, the most appropriate classification is the general regulatory filing fallback category, RNS.
2020-05-07 English
Result of Placing
Capital/Financing Update Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Genedrive PLC, dated May 5, 2020. The content details the successful completion of a share placing, raising gross proceeds of £7.0 million by issuing 8,750,000 new ordinary shares. It specifies the placing price, the role of the Joint Bookrunners (Peel Hunt and finnCap), conditions for admission to trading, and includes a section detailing the resulting shareholdings of Directors/PDMRs (Persons Discharging Managerial Responsibilities) and a substantial shareholder (BGF). This is a specific announcement regarding a capital raising/financing activity, which aligns best with the 'Capital/Financing Update' (CAP) definition. Although it is distributed via RNS, the core subject matter is financing, making CAP more specific than the general 'RNS' fallback. The document is not a full report (10-K, IR) nor is it solely a notice of a dividend or a director's dealing, but a comprehensive announcement about a share issue to raise capital.
2020-05-05 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1353 characters) and begins with 'RNS Number : 9514L', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Price Monitoring Extension' for a security, which is a specific operational notice related to trading mechanisms, not a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or ER). Since it is a general regulatory announcement that doesn't fit the highly specific categories like DIRS, DIV, or ER, the most appropriate fallback category is Regulatory Filings (RNS).
2020-05-05 English
Proposed Placing and Broker Option
Share Issue/Capital Change Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement dated May 5, 2020. The content explicitly details a 'Proposed Placing to raise £7 million' and a 'Proposed Broker Option to raise up to £1 million' through the issuance of new ordinary shares. This activity directly relates to fundraising, capital structure changes, and the issuance of new shares. This fits the definition of Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since the primary focus is raising capital via a placing, CAP is highly relevant. However, the mechanism involves issuing new shares, which aligns perfectly with SHA. Given the context of a formal announcement detailing the mechanics of issuing new shares to raise funds, SHA is the most precise fit for the action being taken (issuing shares), although CAP is also strongly implied. Since the document is a formal regulatory announcement (RNS Number: 9508L) detailing the mechanics of a share issue for fundraising, and SHA specifically covers 'Announcement regarding new share issues, stock splits, or other capital changes,' I will classify it as SHA. It is not a general regulatory filing (RNS) because it is highly specific, nor is it an Earnings Release (ER) or Interim Report (IR).
2020-05-05 English
WHO Prequalification for Genedrive HCV-ID test
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated May 4, 2020. The content is a brief announcement from Genedrive plc regarding its HCV-ID test receiving WHO Prequalification. It is short (under 5,000 characters) and serves as a general regulatory update or news release, rather than a comprehensive financial report (like 10-K or IR) or a specific corporate action filing (like DIV or CAP). Since it is a general regulatory announcement provided via RNS and does not fit into the more specific categories like ER, CT, or DIRS, the most appropriate classification is the general regulatory filing category, RNS.
2020-05-04 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (1370 characters) and originates from 'RNS, the news service of the London Stock Exchange'. It announces a 'Second Price Monitoring Extension' related to trading activity, which is a specific, non-standard regulatory event notification. It does not contain detailed financial results (ER, IR, 10-K) or management changes (MANG). Since it is a general regulatory announcement provided via the RNS service that doesn't fit into the more specific categories like DIRS, DIV, or DLST, the most appropriate classification is the general regulatory fallback category.
2020-05-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.